BioStock: BioInvent delivers double success at ASH and validates platform
BioInvent continues to validate its pipeline with a trio of scientific updates. At ASH, the company presented deep responses for the BI-1206 triple combination in Non-Hodgkin’s lymphoma alongside strong activity for BI-1808 in cutaneous T-cell lymphoma. The latter poster received the “Abstract Achievement Award”. In parallel, a new publication in Clinical Cancer Research reinforces the FcγRIIB-blocking platform. To learn more, BioStock turned to CEO Martin Welschof for a comment.
Read the full interview at biostock.se:
BioInvent delivers double success at ASH and validates platform
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/